Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TSHA-115 is an investigational **gene therapy** developed by Taysha Gene Therapies for the treatment of **glycogen storage diseases**. It is designed to utilize a microRNA (miRNA)-regulated delivery system to provide therapeutic benefit in affected tissues[9][11]. The specific genetic modification, target gene(s), and underlying mechanism are not fully public, but based on Taysha’s general platform, TSHA-115 likely uses an **adeno-associated virus (AAV) vector** system for gene delivery and regulation in metabolic disease tissues. These features may allow for tissue-selective expression and reduced off-target effects, though details remain preclinical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on TSHA-115.